This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Major Hospital In China Purchases Visius Surgical Theatre

- Hospital Expansion Will Highlight Advanced Intraoperative Imaging Suite -

WINNIPEG, March 29, 2012 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced the purchase of a VISIUS Surgical Theatre TM by the First Affiliated Hospital of Zhengzhou University in Zhengzhou City, Henan Province in central China.  Zhengzhou University Hospital is one of the largest hospitals in China, with a neurosurgical department ranked in the top 15 in the country.

Kan Quancheng, President of Zhengzhou University Hospital said: "We believe the VISIUS Surgical Theatre is the essential, leading-edge technology that will take us to the next level of research and clinical practice, especially in Neurosurgery.  We are looking forward to working with IMRIS to achieve our goals". Considering the research opportunities, Cheng Jingliang, Chief Radiologist, added: "Not only the ideal solution for Neurosurgery, "The VISIUS Surgical Theatre will provide us with the best available technology platform for new research in the field of intraoperative MR imaging".

The VISIUS Surgical Theatre at Zhengzhou University Hospital features a high-field (3 Tesla) MR scanner that travels on demand on ceiling-mounted rails into a state-of-the-art neurosurgical OR for imaging without ever moving the patient.  When not needed for intraoperative imaging, the scanner remains in the diagnostic room where it can be used for inpatient and outpatient imaging.  With integrated technologies and control systems for imaging, patient-handling and information management, the VISIUS Surgical Theatre will provide unmatched intraoperative vision to the surgeons at Zhengzhou University Hospital, assist their surgical decision-making and enhance precision in their treatment of patients.

Ke Ning, Vice President and General Manager for IMRIS China, commented on the purchase: "It is an honor to be selected by Zhengzhou University Hospital and to be part of the growth of such an important hospital in China".  David Graves, CEO IMRIS, added: "This is our third project in China, and it serves as a reflection of our commitment to this market and our performance as a global provider of image guided therapy solutions".

About IMRIS

IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre - a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. VISIUS Surgical Theatres serve the neurosurgical, cardiovascular and cerebrovascular markets and have been selected by leading medical institutions around the world. 

SOURCE IMRIS Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs